rr 生物标志物分析原则（NSCL-H）.
vv 晚期或转移性疾病的生物标志物指导治疗原则（NSCL-J）
ww For PS 0–4.
aaa If there is a good response to current therapy, it is reasonable to continue therapy.
bbb Beware of flare phenomenon in subset of patients who discontinue TKI. If disease flare occurs, restart TKI. MET高水平扩增（NSCL-I） High-level MET amplification
Capmatinib
Tepotinib
Crizotinib
a The definition of high-level MET amplification is evolving and may differ according to the assay used for testing. For NGS-based results, a copy number ≥10 is consistent with high-level MET amplification.
b In patients with EGFR-mutant NSCLC who develop high-level MET amplifications, administration of these agents with continuation of osimertinib is acceptable. NCCN-NSCLC-2026V6 NCCN非小细胞肺癌指南导航
